Protective effect of Hachimi-jio-gan against the development of pancreatic fibrosis and oxidative damage in Otsuka Long-Evans Tokushima Fatty rats.
In our previous study, the polyherbal drug Hachimi-jio-gan was reported to possess a protective effect against the progression of diabetic nephropathy by attenuating glucose toxicity and renal damage with a type 2 diabetic model, Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Based on these findings, this study was undertaken to reveal the effect of Hachimi-jio-gan on pancreatic damage focusing on fibrosis and oxidative stress in type 2 diabetes. OLETF rats were orally administered Hachimi-jio-gan for 32 weeks, and we assessed the changes in the serum glucose level every 8 weeks, as well as those of body weight, and food and water consumption every 4 weeks. In addition, pancreatic wet weight, insulin content, and Western blot analyses of transforming growth factor-beta(1), fibronectin, and nuclear factor-kappaB-related inflammatory enzymes, such as inducible nitric oxide synthesis and cyclooxygenase-2, were also performed in the pancreas. As a consequence, long-term treatment with Hachimi-jio-gan had a hypoglycemic effect, reducing pancreatic atrophy and fibrosis, and ameliorating the oxidative status. Therefore, this may provide evidence that Hachimi-jio-gan is a therapeutic target for preventing the development of pancreatic damage concomitant with hyperglycemia in type 2 diabetes.
Yamabe
Noriko
N
Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Yokozawa
Takako
T
D000284:Administration, Oral; D000818:Animals; D001284:Atrophy / Q000517:prevention & control; D001786:Blood Glucose / Q000187:drug effects; D015153:Blotting, Western; D051546:Cyclooxygenase 2 / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000494:pharmacology* / Q000627:therapeutic use; D005353:Fibronectins / Q000378:metabolism; D005355:Fibrosis / Q000209:etiology / Q000517:prevention & control*; D007328:Insulin / Q000378:metabolism; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D010182:Pancreatic Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D051381:Rats; D020334:Rats, Inbred OLETF; D020318:Rats, Long-Evans; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
D001786:Blood Glucose; D004365:Drugs, Chinese Herbal; D005353:Fibronectins; D007328:Insulin; D053773:Transforming Growth Factor beta1; C054591:hachimijiogan; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2